A study of RRMS patients, treated with natalizumab, reported improvements in physical and psychological health-related quality of life and treatment satisfaction.
The improvements were sustained over a period of three years in patients with continuous natalizumab (Tysabri) treatment, supporting the long-term efficacy of natalizumab in real-world settings.
The US study evaluated health-related quality of life and treatment satisfaction in patients receiving 300mg of intravenous natalizumab, every four weeks, in a clinical setting. Patients completed surveys at the start and then every six months, for three years and reported the following measures, Short Form-12 Version 2 (SF-12v2), Multiple Sclerosis Impact Scale (MSIS-29), and Treatment Satisfaction Questionnaire for Medication.
In this study, 120 patients completed more than three years treatment of natalizumab. Significant health-related quality of life improvements were evident from the start of the study to year three by increases in the SF-12v2 Physical Component Summary (PCS) and Mental Component Summary scores (P<0.01), as well as decreases in MSIS-29 physical and psychological scores (P<0.0001).
Patients with less physical disability (baseline Disease Steps [DS] 0–2) saw more significant improvement (P<0.05). Physical health-related quality of life outcomes in patients with baseline DS 3-6 remained stable over three years. Treatment satisfaction increased significantly from the start of the study to year one (P<0.0001) and was maintained in the following two years.
Researchers concluded that lower baseline disease activity and earlier treatment were related to better outcomes, indicating the importance of starting natalizumab early in the disease course.
This study – “Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis” – was published in the journal, Patient Preference and Adherence.